Lacibloc Drug Interactions

Lacidipine is highly protein bound (more than 95%) to albumin and alpha-1-glycoprotein.
As with other dihydropyridines, Lacidipine should not be taken with grapefruit juice as bioavailability may be altered.
In clinical studies in patients with a renal transplant treated with cyclosporin, Lacidipine reversed the decrease in renal plasma flow and glomerular filtration rate induced by cyclosporin.
4 mg: Co-administration of lacidipine with other agents recognised to have a hypotensive effect, including anti-hypertensive agents, (e.g. diuretics, beta-blockers, or ACE inhibitors), may have an additive hypotensive effect. However, no problems have been identified in studies with common antihyperspecific interaction tensive agents (e.g. beta-blockers and diuretics) or with digoxin, tolbutamide or warfarin. The plasma level of lacidipine may be increased by simultaneous administration of cimetidine.
Lacidipine is known to be metabolised by cytochrome CYP3A4 and, therefore, significant inhibitors and inducers of CYP3A4 administered concurrently may interact with the metabolism and elimination of lacidipine.
6 mg: Lacidipine may enhance the antihypertensive effects of other antihypertensive drugs such as beta blockers although the combination is generally well tolerated. Enhanced antihypertensive effects may also be seen with concomitant used of drugs such as aldesleukin and antipsychotics that cause hypotension. Lacidipine may modify insulin and glucose responses and therefore diabetic patients may need to adjust their antidiabetic treatment when receiving Lacidipine. Lacidipine is extensively metabolized in the liver by the cytochrome P-450 enzyme system, and interactions may occur other drugs, such as quinidine, sharing the same metabolic pathway, and with enzyme inducers, such as carbamazepine, phenytoin, and rifampicin, and enzyme inhibitors, such as cimetidine and erythromycin.